Literature DB >> 10385021

Short-term treatment of pertussis with azithromycin in infants and young children.

A Baće1, T Zrnić, J Begovac, N Kuzmanović, J Culig.   

Abstract

A prospective, open, noncomparative study was conducted to assess the efficacy and safety of azithromycin given once daily for 3 or 5 days to eradicate Bordetella pertussis from the upper respiratory tract of infants and young children. Seventeen children received azithromycin in a dose of 10 mg/kg on day 1 followed by 5 mg/kg once daily for four consecutive days, and 20 were given 10 mg/kg once daily for 3 days. Seven days after the initiation of therapy, 33 of 35 (94.3%) patients had negative cultures for Bordetella pertussis. On day 14, cultures from all 34 evaluable patients were negative. These findings suggest that a controlled, comparative study of erythromycin versus short-term administration of azithromycin is justified.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10385021     DOI: 10.1007/s100960050281

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  5 in total

Review 1.  Pertussis vaccination for health care workers.

Authors:  Thomas J Sandora; Courtney A Gidengil; Grace M Lee
Journal:  Clin Microbiol Rev       Date:  2008-07       Impact factor: 26.132

Review 2.  Diagnosis and management of pertussis.

Authors:  Alberto E Tozzi; Lucia Pastore Celentano; Marta Luisa Ciofi degli Atti; Stefania Salmaso
Journal:  CMAJ       Date:  2005-02-15       Impact factor: 8.262

Review 3.  Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies.

Authors:  Seema Mattoo; James D Cherry
Journal:  Clin Microbiol Rev       Date:  2005-04       Impact factor: 26.132

Review 4.  The association of erythromycin and infantile hypertrophic pyloric stenosis: causal or coincidental?

Authors:  Manfred Hauben; Guy W Amsden
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

5.  Macrolides: A Canadian Infectious Disease Society position paper.

Authors:  S McKenna; G Evans
Journal:  Can J Infect Dis       Date:  2001-07
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.